Navigation Links
Bioengineers develop bacterial strain to increase ethanol biofuel production
Date:12/10/2010

Georgia, US - A team of Bioengineers in the United States have modified a strain of bacteria to increase its ability to produce ethanol. The research, published in Biotechnology and Bioengineering, reveals how adaptation and metabolic engineering can be combined for strain improvement, a positive development for the biofuel industry.

The team focused their research on Zymomonas mobilis, a bacterium noted for its bio-ethanol producing potential. However, the team believed that ethanol production could be increased through improvement of xylose fermentation.

"Zymomonas mobilis is a superb ethanol producer with productivity exceeding yeast strains by several fold," said lead author Rachel Chen from the Georgia Institute of Technology. "In this study we sought to improve ethanol production by enhancing the ability of Z. mobilis to use and ferment xylose. Fermenting xylose at high concentration could in turn increase ethanol concentration, resulting in much improved productivity."

The team found that by metabolically altering the strain, sugar fermentation time was reduced from over 110 hours to about 35 hours. This improvement in fermentation allowed the strain to ferment higher concentrations of xylose.

"This demonstrated increase in fermentation and xylose utilization enabled us to produce ethanol to a concentration of 9% (w/v), the highest ever shown for this organism in mixed sugar fermentation," said Chen.

This research also investigated the underlying mechanism for the improvement. Interestingly, by adapting a strain in a high concentration of xylose, significant alterations of metabolism occurred.

One noticeable change was reduced levels of xylitol, a byproduct of xylose fermentation which can inhibit the strain's xylose metabolism. In addition, the first step of xylose metabolism, believed to be the rate-limiting step, was accelerated 4-8 times in the adapted strain, with the net effect of chann
'/>"/>

Contact: Ben Norman
Lifesciencenews@wiley.com
44-012-437-70375
Wiley-Blackwell
Source:Eurekalert

Page: 1 2

Related biology technology :

1. QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet Digital™ PCR Platform and Establish Commercial Operations by 2011
2. Shrink Nanotechnologies Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform
3. Shrink Nanotechnologies Enters Into Exclusive Development and Manufacturing Agreement With EV Group to Commercialize Stem Disc Platform
4. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
5. Pitt-led team develops nanoscale light sensor compatible with Etch-a-Sketch nanoelectronic platform
6. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
7. Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
8. Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure
9. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
10. U.S. Government Grants Awarded for Further Development of Adult Stem Cell Products
11. Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... (PRWEB) May 28, 2015 DryLet, ... use in applications such as animal waste reduction, ... oil reduction in wastewater treatment plants and restaurant ... the World Pork Expo, June 3-5 in Des ... year in a Wall Street Journal article because ...
(Date:5/28/2015)... N.J. , May 28, 2015  PDS ... a cancer immunotherapy treatment targeting HPV-16, has generated ... Currently, pre-cervical cancer is treated by ... a simple and effective non-surgical alternative. Results show ... mechanisms (T-cells) to recognize, target, and kill precancerous ...
(Date:5/28/2015)... 2015 Biscayne Pharmaceuticals, Inc ., today ... growth hormone-releasing hormone (GHRH) technology will be discussed in a ... Meeting. The data show that the family of receptors ... is present on many primary breast cancer cells regardless ... antagonists could have broad anti-cancer potential in breast cancer. ...
(Date:5/28/2015)... and London (PRWEB) May 28, 2015 ... of Computer Aided Engineering software, announced today it ... Inc. (PSRI). CD-adapco will provide state-of-the-art engineering simulation ... will share their expertise and experiences in analyzing ... refining industry members and advance the understanding of ...
Breaking Biology Technology:DryLet to Showcase Patented ManureMagic™ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... Visionsense Corp. announces,FDA 510(k) Clearance of ... The system is based on a miniature ... Minimal Invasive,laparoscopic and endoscopic Surgery (MIS)., ... MIS surgical,procedures that are under served by ...
... Therapeutics announced today,the initiation of a Phase ... orally bioavailable small molecule in development for ... I study will evaluate the safety,tolerability and ... blind, placebo controlled, single ascending dose design ...
... March 18 TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ... II study of,NGX267, a muscarinic agonist in development ... The company is conducting a randomized, double-blind,placebo-controlled, ... evaluate,the safety, tolerability and efficacy of this once-a-day ...
Cached Biology Technology:Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... As drylands of the world become even drier, water will not ... the soil will likely be affected, and their imbalance could affect ... That includes people living in Arizona, who may be in for ... study published in Nature that details how soil changes ...
... teams at the Polytechnic Institute of New York University ... understand and influence the complex swimming behaviors of schooling ... of mechanical and aerospace engineering at NYU-Poly, published two ... These studies are the latest in a ...
... scent marking to advertise their territory they urinate at ... It has been suggested that markings serves to attract females ... males, scent marks appear to be a secondary sexual trait, ... mate. When male house mice are subordinate or sick, for ...
Cached Biology News:Plant production could decline as climate change affects soil nutrients 2The secret's in the (robotic) stroke 2The secret's in the (robotic) stroke 3Scent marking 2
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... are derived from the Spodoptera frugiperda Sf21 cell ... in transfections, plaque assays, virus production, and protein ... that optimizes recovery of viable cells after thawing. ... Insect Cell Medium and can also be grown ...
...
... pLivSelect is a direct antibiotic-based selection system ... on colony survival, eliminating the need for ... process provides close to 100% accuracy in ... platform for robot colony picking. This cloning ...
Biology Products: